SAN FRANCISCO, Jan 8 – Structural Genomix’ deal to jointly develop a new protein analysis system with Caliper Technologies represents one of two types of transactions the company is looking to forge, Linda Grais, Structural Genomix’ executive vice president and founder, said Monday.

"In some deals, we will be licensing technology in and in others we will sell information about protein structures," said Grais, who was attending the JP Morgan H&Q conference.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.